(3,5-Dimethoxy-phenyl)-piperazin-1-yl-methanone | 181047-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-Dimethoxy-phenyl)-piperazin-1-yl-methanone
• 英文别名: 1-(3,5-Dimethoxybenzoyl)piperazine；(3,5-dimethoxyphenyl)-piperazin-1-ylmethanone
• CAS: 181047-33-6
• 化学式: C₁₃H₁₈N₂O₃
• mdl: MFCD02212054
• 分子量: 250.298
• InChiKey: YHDXJIYVDCHDIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3,5-Dimethoxy-phenyl)-piperazin-1-yl-methanone 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以82%的产率得到1-(3,5-二甲氧基苄基)哌嗪
  参考文献：
  名称：

  一种实用而有效的合成6-氨基甲基-4-氧代-4,5,6,7-四氢吲哚作为新型CNS试剂前体的途径

  摘要：

  从2，5-二甲氧基苯甲酸开始，我们描述了一种实用且有效的合成6-氨基甲基-4-氧代四氢吲哚的途径，其总收率良好至50-30％。

  DOI：

  10.1016/0040-4039(96)01028-3
• 作为产物：
  描述：

  3,5-二甲氧基苯甲酰氯 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.17h， 生成 (3,5-Dimethoxy-phenyl)-piperazin-1-yl-methanone
  参考文献：
  名称：

  靶向肝X受体的聚焦化合物文库的筛选在具有逆激动剂和降解活性的胰腺癌识别配体中

  摘要：

  胰腺导管腺癌（PDAC）是胰腺癌的主要形式。PDAC的窝藏在致癌突变KRAS基因，以及不断努力其突变蛋白产物直接靶向抑制肿瘤生长是一个优先不仅在胰腺癌，但在其他恶性肿瘤如肺癌和结肠直肠癌，其中KRAS通常也是突变的。直接靶向KRAS的另一种策略是鉴定和靶向参与KRAS失调下游癌症标志失调的可药用受体。肝X受体（LXR）是配体调节的转录因子核受体家族的成员，参与对在关键的癌症相关过程中起作用的基因的调节，这些过程包括胆固醇转运，脂质和葡萄糖代谢以及炎症和免疫反应。通过小分子配体对LXR的调节已成为直接靶向肿瘤细胞或肿瘤微环境中的基质细胞和免疫细胞的有前途的方法。我们先前已经证明，两种LXR亚型（LXRβ）中只有一种在胰腺癌细胞中表达，并以可用的合成配体靶向LXR可以阻止PDAC细胞的增殖和肿瘤形成。在预计将停靠在LXRβ配体结合口袋中的类药物小分子聚焦文库的屏幕中，我们鉴定了两个新的LXR配

  DOI：

  10.1021/acschembio.0c00546

文献信息

• [EN] SMALL MOLECULE LIVER X RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS À PETITES MOLÉCULE DU RÉCEPTEUR NUCLÉAIRE DES OXYSTÉROLS ET LEURS UTILISATIONS
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2021046034A1

  公开（公告）日：2021-03-11

  Small molecule liver X receptor (LXR) modulators, and derivatives thereof, exhibit activity against tumor cells and less or no activity against dividing non-malignant cells, target the liver X receptor and disrupt key metabolic pathways preferred by cancer cells, and activate a newly discovered cell death mechanism which is distinct from the cell death induced by chemotherapeutic agents. These compounds can thus be a less toxic alternative to chemotherapy and can be used in combination with chemotherapy to increase efficacy and decrease the likelihood of cancer cells developing resistance. Moreover, they can be used as second-line treatments when chemotherapies are ineffective or if cancer cells develop resistance over time.

  小分子肝X受体（LXR）调节剂及其衍生物对肿瘤细胞具有活性，对分裂的非恶性细胞活性较低或无活性，靶向肝X受体并破坏癌细胞首选的关键代谢途径，并激活一种新发现的细胞死亡机制，该机制与化疗药物引起的细胞死亡不同。因此，这些化合物可以作为比化疗更少毒副作用的选择，并可与化疗结合使用，以提高疗效并降低癌细胞产生抗药性的可能性。此外，当化疗无效或癌细胞随时间产生抗药性时，它们可以作为二线治疗方法。
• Chemical mechanical planarization for tungsten-containing substrates
  申请人：AIR PRODUCTS AND CHEMICALS, INC.

  公开号：EP2779217A2

  公开（公告）日：2014-09-17

  Chemical mechanical polishing (CMP) compositions for polishing tungsten or tungsten-containing substrates comprise an abrasive, at least one solid catalyst, a chemical additive selected from the groups consisting of piperazine derivatives, salts of cyanate, and combinations thereof; and a liquid carrier. Systems and processes use the aqueous formulations for polishing tungsten or tungsten-containing substrates.

  用于抛光钨或含钨基材的化学机械抛光（CMP）组合物包括磨料、至少一种固体催化剂、一种选自哌嗪衍生物、氰酸盐及其组合的化学添加剂；以及一种液体载体。系统和工艺使用水性制剂抛光钨或含钨基材。
• Design, Synthesis, and Biological Activity of Novel, Potent, and Selective (Benzoylaminomethyl)thiophene Sulfonamide Inhibitors of c-Jun-N-Terminal Kinase
  作者：Thomas Rückle、Marco Biamonte、Tania Grippi-Vallotton、Steve Arkinstall、Yves Cambet、Montserrat Camps、Christian Chabert、Dennis J. Church、Serge Halazy、Xuliang Jiang、Isabelle Martinou、Anthony Nichols、Wolfgang Sauer、Jean-Pierre Gotteland

  DOI：10.1021/jm031112e

  日期：2004.12.1

  Several lines of evidence support the hypothesis that c-Jun N-terminal kinases (JNKs) play a critical role in a wide range of disease states including cell death (apoptosis)-related and inflammatory disorders (epilepsy, brain, heart and renal ischemia, neurodegenerative diseases, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel syndrome). The screening of a compound collection led to the identification of a 2-(benzoylaminomethyl)thiophene sulfonamide (AS004509, compound I) as a potent and selective JNK inhibitor. Chemistry and structure-activity relationship (SAR) studies performed around this novel kinase-inhibiting motif indicated that the left and central parts of the molecule were instrumental to maintaining potency at the enzyme. Accordingly, we investigated the JNK-inhibiting properties of a number of variants of the right-hand moiety of the molecule, which led to the identification of 2-(benzoylaminomethyl)thiophene sulfonamide benzotriazole (AS600292, compound 50a), the first potent and selective JNK inhibitor of this class which demonstrates a protective action against neuronal cell death induced by growth factor and serum deprivation.
• Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine
  作者：Yuanyuan Shan、Jinyun Dong、Xiaoyan Pan、Lin Zhang、Jie Zhang、Yalin Dong、Maoyi Wang

  DOI：10.1016/j.ejmech.2015.09.034

  日期：2015.11

  A series of N,N'-dibenzoylpiperazine derivatives incorporated with 1H-indazol-3-amine have been designed, synthesized and evaluated as novel Bcr-Abl inhibitors. Several title compounds exhibited potent inhibitory activity against Bcr-Abl wild type as well as T315I mutant. Two compounds, ha and 12c, strongly suppressed the activity of native and mutant Bcr-Abl. In particular, ha exhibited comparable potency with that of Imatinib. It potently inhibited both Bcr-Abl(WT) and Bcr-AbI(T3151) with IC50 values of 0.014 mu M and 0.45 mu M, respectively. Furthermore, compound ha also inhibited the proliferation of K562 leukemia cancer cells. Therefore, it could serve as promising lead compound for further optimization of Bcr-Abl(WT) and Bcr-Abl(T3151) inhibitors. (C) 2015 Elsevier Masson SAS. All rights reserved.
• US20140273458A1
  申请人：——

  公开号：US20140273458A1

  公开（公告）日：2014-09-18